{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:59:32Z","timestamp":1788566372065,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T00:00:00Z","timestamp":1539561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T00:00:00Z","timestamp":1539561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Using targeted NMR spectroscopy of 227 fasting serum metabolic traits, we searched for novel metabolic signatures of renal function in 926 type 2 diabetics (T2D) and 4838 non-diabetic individuals from four independent cohorts. We furthermore investigated longitudinal changes of metabolic measures and renal function and associations with other T2D microvascular complications. 142 traits correlated with glomerular filtration rate (eGFR) after adjusting for confounders and multiple testing: 59 in diabetics, 109 in non-diabetics with 26 overlapping. The amino acids glycine and phenylalanine and the energy metabolites citrate and glycerol were negatively associated with eGFR in all the cohorts, while alanine, valine and pyruvate depicted opposite association in diabetics (positive) and non-diabetics (negative). Moreover, in all cohorts, the triglyceride content of different lipoprotein subclasses showed a negative association with eGFR, while cholesterol, cholesterol esters (CE), and phospholipids in HDL were associated with better renal function. In contrast, phospholipids and CEs in LDL showed positive associations with eGFR only in T2D, while phospholipid content in HDL was positively associated with eGFR both cross-sectionally and longitudinally only in non-diabetics. In conclusion, we provide a wide list of kidney function\u2013associated metabolic traits and identified novel metabolic differences between diabetic and non-diabetic kidney disease.<\/jats:p>","DOI":"10.1038\/s41598-018-33507-7","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T10:14:36Z","timestamp":1539080076000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Circulating metabolic biomarkers of renal function in diabetic and non-diabetic populations"],"prefix":"10.1038","volume":"8","author":[{"given":"Clara","family":"Barrios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9693-1859","authenticated-orcid":false,"given":"Jonas","family":"Zierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"W\u00fcrtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toomas","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Metspalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Thorand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Meisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Waldenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Raitakari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terho","family":"Lehtim\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol","family":"Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Pedro-Botet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"K\u00e4h\u00f6nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Ala-Korpela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabi","family":"Kastenm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim D.","family":"Spector","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9790-0571","authenticated-orcid":false,"given":"Cristina","family":"Menni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,15]]},"reference":[{"key":"33507_CR1","doi-asserted-by":"crossref","first-page":"e000308","DOI":"10.1136\/bmjopen-2011-000308","volume":"1","author":"Ca O\u2019Callaghan","year":"2011","unstructured":"O\u2019Callaghan, Ca, Shine, B. & Lasserson, D. S. Chronic kidney disease: a large-scale population-based study of the effects of introducing the CKD-EPI formula for eGFR reporting. BMJ Open 1, e000308\u2013e000308 (2011).","journal-title":"BMJ Open"},{"key":"33507_CR2","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296\u2013305 (2004).","journal-title":"N. Engl. J. Med."},{"key":"33507_CR3","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","volume":"370","author":"EW Gregg","year":"2014","unstructured":"Gregg, E. W. et al. Changes in diabetes-related complications in the United States, 1990\u20132010. N Engl J Med 370, 1514\u20131523 (2014).","journal-title":"N Engl J Med"},{"key":"33507_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.jdiacomp.2015.06.016","volume":"29","author":"Y Zhang","year":"2015","unstructured":"Zhang, Y., Zhang, S. & Wang, G. Metabolomic biomarkers in diabetic kidney diseases\u2013A systematic review. J. Diabetes Complications 29, 1345\u201351 (2015).","journal-title":"J. Diabetes Complications"},{"key":"33507_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.abb.2015.10.006","volume":"589","author":"C Barrios","year":"2016","unstructured":"Barrios, C., Spector, T. D. & Menni, C. Blood, urine and faecal metabolite profiles in the study of adult renal disease. Arch. Biochem. Biophys. 589, 81\u201392 (2016).","journal-title":"Arch. Biochem. Biophys."},{"key":"33507_CR6","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1681\/ASN.2014111099","volume":"27","author":"P Sekula","year":"2016","unstructured":"Sekula, P. et al. A Metabolome-Wide Association Study of Kidney Function and Disease in the General Population. J. Am. Soc. Nephrol. 27, 1175\u201388 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"33507_CR7","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/clpt.2013.158","volume":"94","author":"V-P M\u00e4kinen","year":"2013","unstructured":"M\u00e4kinen, V.-P. et al. Metabolic phenotyping of diabetic nephropathy. Clin. Pharmacol. Ther. 94, 566\u20139 (2013).","journal-title":"Clin. Pharmacol. Ther."},{"key":"33507_CR8","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1021\/pr201036j","volume":"11","author":"V-P M\u00e4kinen","year":"2012","unstructured":"M\u00e4kinen, V.-P. et al. Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study). J. Proteome Res. 11, 1782\u201390 (2012).","journal-title":"J. Proteome Res."},{"key":"33507_CR9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/msb4100205","volume":"4","author":"P Soininen","year":"2008","unstructured":"Soininen, P. et al. 1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol. Syst. Biol. 4, 167 (2008).","journal-title":"Mol. Syst. Biol."},{"key":"33507_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/joim.12026","volume":"273","author":"V-P M\u00e4kinen","year":"2013","unstructured":"M\u00e4kinen, V.-P. et al. Triglyceride-cholesterol imbalance across lipoprotein subclasses predicts diabetic kidney disease and mortality in type 1 diabetes: the FinnDiane Study. J. Intern. Med. 273, 383\u201395 (2013).","journal-title":"J. Intern. Med."},{"key":"33507_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000447954","volume":"44","author":"M Darshi","year":"2016","unstructured":"Darshi, M., Van Espen, B. & Sharma, K. Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer. Am. J. Nephrol. 44, 92\u2013103 (2016).","journal-title":"Am. J. Nephrol."},{"key":"33507_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/srep11998","volume":"5","author":"T Wei","year":"2015","unstructured":"Wei, T. et al. Metabonomic analysis of potential biomarkers and drug targets involved in diabetic nephropathy mice. Sci. Rep. 5, 11998 (2015).","journal-title":"Sci. Rep."},{"key":"33507_CR13","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1073\/pnas.97.3.1242","volume":"97","author":"N M\u00f8ller","year":"2000","unstructured":"M\u00f8ller, N., Meek, S., Bigelow, M., Andrews, J. & Nair, K. S. The kidney is an important site for in vivo phenylalanine-to-tyrosine conversion in adult humans: A metabolic role of the kidney. Proc. Natl. Acad. Sci. USA 97, 1242\u20136 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"33507_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nm.2307","volume":"17","author":"TJ Wang","year":"2011","unstructured":"Wang, T. J. et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 17, 448\u201353 (2011).","journal-title":"Nat. Med."},{"key":"33507_CR15","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2337\/db12-0495","volume":"62","author":"A Floegel","year":"2013","unstructured":"Floegel, A. et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 62, 639\u2013648 (2013).","journal-title":"Diabetes"},{"key":"33507_CR16","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2337\/db11-1378","volume":"61","author":"A Stancakova","year":"2012","unstructured":"Stancakova, A. et al. Hyperglycemia and a Common Variant of GCKR Are Associated With the Levels of Eight Amino Acids in 9,369 Finnish Men. Diabetes 61, 1895\u20131902 (2012).","journal-title":"Diabetes"},{"key":"33507_CR17","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2337\/dc15-2251","volume":"39","author":"M Guasch-Ferr\u00e9","year":"2016","unstructured":"Guasch-Ferr\u00e9, M. et al. Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis. Diabetes Care 39, 833\u2013846 (2016).","journal-title":"Diabetes Care"},{"key":"33507_CR18","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.114.013116","volume":"131","author":"P Wurtz","year":"2015","unstructured":"Wurtz, P. et al. Metabolite Profiling and Cardiovascular Event Risk: A Prospective Study of 3 Population-Based Cohorts. Circulation 131, 774\u2013785 (2015).","journal-title":"Circulation"},{"key":"33507_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1042\/cs0450089","volume":"45","author":"GA Young","year":"1973","unstructured":"Young, G. A. & Parsons, F. M. Impairment of phenylalanine hydroxylation in chronic renal insufficiency. Clin. Sci. 45, 89\u201397 (1973).","journal-title":"Clin. Sci."},{"key":"33507_CR20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1523-1755.2004.00778.x","volume":"66","author":"Y Boirie","year":"2004","unstructured":"Boirie, Y., Albright, R., Bigelow, M. & Nair, K. S. Impairment of phenylalanine conversion to tyrosine in end-stage renal disease causing tyrosine deficiency. Kidney Int. 66, 591\u2013596 (2004).","journal-title":"Kidney Int."},{"issue":"6","key":"33507_CR21","doi-asserted-by":"publisher","first-page":"1586S","DOI":"10.1093\/jn\/137.6.1586S","volume":"137","author":"Joel D. Kopple","year":"2007","unstructured":"Kopple, J. D. Phenylalanine and tyrosine metabolism in chronic kidney failure. J. Nutr. 137 1586S\u20131590S; discussion 1597S\u20131598S (2007).","journal-title":"The Journal of Nutrition"},{"key":"33507_CR22","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1152\/ajplegacy.1970.219.3.584","volume":"219","author":"RF Pitts","year":"1970","unstructured":"Pitts, R. F., Damian, A. C. & MacLeod, M. B. Synthesis of serine by rat kidney in vivo and in vitro. Am. J. Physiol. 219, 584\u20139 (1970).","journal-title":"Am. J. Physiol."},{"key":"33507_CR23","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1172\/JCI109771","volume":"65","author":"A Tizianello","year":"1980","unstructured":"Tizianello, A., De Ferrari, G., Garibotto, G., Gurreri, G. & Robaudo, C. Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency. J. Clin. Invest. 65, 1162\u201373 (1980).","journal-title":"J. Clin. Invest."},{"key":"33507_CR24","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1172\/JCI115997","volume":"90","author":"I Magnusson","year":"1992","unstructured":"Magnusson, I., Rothman, D. L., Katz, L. D., Shulman, R. G. & Shulman, G. I. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J. Clin. Invest. 90, 1323\u20137 (1992).","journal-title":"J. Clin. Invest."},{"key":"33507_CR25","first-page":"F301","volume":"255","author":"S Brennan","year":"1988","unstructured":"Brennan, S., Hering-Smith, K. & Hamm, L. L. Effect of pH on citrate reabsorption in the proximal convoluted tubule. Am. J. Physiol. 255, F301\u20136 (1988).","journal-title":"Am. J. Physiol."},{"key":"33507_CR26","doi-asserted-by":"publisher","first-page":"e85445","DOI":"10.1371\/journal.pone.0085445","volume":"9","author":"J-A Kim","year":"2014","unstructured":"Kim, J.-A. et al. 1H NMR-based metabolite profiling of plasma in a rat model of chronic kidney disease. PLoS One 9, e85445 (2014).","journal-title":"PLoS One"},{"key":"33507_CR27","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1681\/ASN.2013020126","volume":"24","author":"K Sharma","year":"2013","unstructured":"Sharma, K. et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J. Am. Soc. Nephrol. 24, 1901\u201312 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"33507_CR28","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","volume":"58","author":"B Verg\u00e8s","year":"2015","unstructured":"Verg\u00e8s, B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia 58, 886\u201399 (2015).","journal-title":"Diabetologia"},{"key":"33507_CR29","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1262-3636(07)70213-6","volume":"31","author":"B Verg\u00e8s","year":"2005","unstructured":"Verg\u00e8s, B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab. 31, 429\u201339 (2005).","journal-title":"Diabetes Metab."},{"key":"33507_CR30","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1525-139X.2007.00340.x","volume":"20","author":"C Baigent","year":"2007","unstructured":"Baigent, C., Landray, M. J. & Wheeler, D. C. Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials. Semin. Dial. 20, 498\u2013503 (2007).","journal-title":"Semin. Dial."},{"key":"33507_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/ndt\/gfl580","volume":"22","author":"C Baigent","year":"2007","unstructured":"Baigent, C. & Landray, M. Which cardiovascular risk factors matter in chronic kidney disease? Nephrol. Dial. Transplant 22, 9\u201311 (2007).","journal-title":"Nephrol. Dial. Transplant"},{"key":"33507_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1755-6686.2010.00173.x","volume":"Suppl 1","author":"D Lewis","year":"2010","unstructured":"Lewis, D., Haynes, R. & Landray, M. J. Lipids in chronic kidney disease. J. Ren. Care 36 Suppl 1, 27\u201333 (2010).","journal-title":"J. Ren. Care 36"},{"key":"33507_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2174\/1874192401105010041","volume":"5","author":"V Tsimihodimos","year":"2011","unstructured":"Tsimihodimos, V., Mitrogianni, Z. & Elisaf, M. Dyslipidemia associated with chronic kidney disease. Open Cardiovasc. Med. J. 5, 41\u20138 (2011).","journal-title":"Open Cardiovasc. Med. J."},{"key":"33507_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.atherosclerosis.2015.06.048","volume":"242","author":"C Barrios","year":"2015","unstructured":"Barrios, C. et al. Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease. Atherosclerosis 242, 37\u201344 (2015).","journal-title":"Atherosclerosis"},{"key":"33507_CR35","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/14728222.2017.1369961","volume":"21","author":"M Berm\u00fadez-L\u00f3pez","year":"2017","unstructured":"Berm\u00fadez-L\u00f3pez, M. et al. New perspectives on CKD-induced dyslipidemia. Expert Opin. Ther. Targets 21, 967\u2013976 (2017).","journal-title":"Expert Opin. Ther. Targets"},{"key":"33507_CR36","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet (London, England) 377, 2181\u201392 (2011).","journal-title":"Lancet (London, England)"},{"key":"33507_CR37","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstr\u00f6m","year":"2009","unstructured":"Fellstr\u00f6m, B. C. et al. Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. N. Engl. J. Med. 360, 1395\u20131407 (2009).","journal-title":"N. Engl. J. Med."},{"key":"33507_CR38","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238\u201348 (2005).","journal-title":"N. Engl. J. Med."},{"key":"33507_CR39","doi-asserted-by":"publisher","first-page":"c214","DOI":"10.1159\/000329509","volume":"119","author":"RG Bowden","year":"2011","unstructured":"Bowden, R. G. et al. Reverse epidemiology of lipid-death associations in a cohort of end-stage renal disease patients. Nephron. Clin. Pract. 119, c214\u20139 (2011).","journal-title":"Nephron. Clin. Pract."},{"key":"33507_CR40","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.2337\/dc13-1467","volume":"37","author":"B Bouillet","year":"2014","unstructured":"Bouillet, B. et al. Glycation of apolipoprotein C1 impairs its CETP inhibitory property: pathophysiological relevance in patients with type 1 and type 2 diabetes. Diabetes Care 37, 1148\u201356 (2014).","journal-title":"Diabetes Care"},{"key":"33507_CR41","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00125-005-0088-0","volume":"49","author":"R de Vries","year":"2006","unstructured":"de Vries, R. et al. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia 49, 398\u2013404 (2006).","journal-title":"Diabetologia"},{"key":"33507_CR42","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/ATVBAHA.116.307385","volume":"36","author":"J Apro","year":"2016","unstructured":"Apro, J. et al. Impaired Cholesterol Efflux Capacity of High-Density Lipoprotein Isolated From Interstitial Fluid in Type 2 Diabetes Mellitus-Brief Report. Arterioscler. Thromb. Vasc. Biol. 36, 787\u201391 (2016).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"33507_CR43","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/dmrr.895","volume":"24","author":"H Zhou","year":"2008","unstructured":"Zhou, H., Tan, K. C. B., Shiu, S. W. M. & Wong, Y. Cellular cholesterol efflux to serum is impaired in diabetic nephropathy. Diabetes. Metab. Res. Rev. 24, 617\u201323 (2008).","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"33507_CR44","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1525-139X.2009.00661.x","volume":"22","author":"ND Vaziri","year":"2009","unstructured":"Vaziri, N. D. Causes of dysregulation of lipid metabolism in chronic renal failure. Semin. Dial. 22, 644\u201351 (2009).","journal-title":"Semin. Dial."},{"key":"33507_CR45","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrneph.2015.180","volume":"12","author":"ND Vaziri","year":"2016","unstructured":"Vaziri, N. D. HDL abnormalities in nephrotic syndrome and chronic kidney disease. Nat. Rev. Nephrol. 12, 37\u201347 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"33507_CR46","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1161\/01.ATV.17.11.2685","volume":"17","author":"N Fournier","year":"1997","unstructured":"Fournier, N. et al. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler. Thromb. Vasc. Biol. 17, 2685\u201391 (1997).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"33507_CR47","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1161\/ATVBAHA.115.305504","volume":"35","author":"AP Agarwala","year":"2015","unstructured":"Agarwala, A. P. et al. High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease. Arterioscler. Thromb. Vasc. Biol. 35, 1515\u20131519 (2015).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"33507_CR48","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/ije\/dyr207","volume":"42","author":"A Moayyeri","year":"2013","unstructured":"Moayyeri, A., Hammond, C. J., Valdes, A. M. & Spector, T. D. Cohort Profile: TwinsUK and Healthy Ageing Twin Study. Int. J. Epidemiol. 42, 76\u201385 (2013).","journal-title":"Int. J. Epidemiol."},{"key":"33507_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1055\/s-2005-858235","volume":"67","author":"R Holle","year":"2005","unstructured":"Holle, R., Happich, M., L\u00f6wel, H. & Wichmann, H. KORA - A Research Platform for Population Based Health Research. Gesundheitswesen 67, 19\u201325 (2005).","journal-title":"Gesundheitswesen"},{"key":"33507_CR50","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/ije\/dym225","volume":"37","author":"OT Raitakari","year":"2008","unstructured":"Raitakari, O. T. et al. Cohort profile: The cardiovascular risk in young Finns study. Int. J. Epidemiol. 37, 1220\u20131226 (2008).","journal-title":"Int. J. Epidemiol."},{"key":"33507_CR51","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604\u2013612 (2009).","journal-title":"Ann. Intern. Med."},{"key":"33507_CR52","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1161\/CIRCGENETICS.114.000216","volume":"8","author":"P Soininen","year":"2015","unstructured":"Soininen, P., Kangas, A. J., W\u00fcrtz, P., Suna, T. & Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. Circ. Cardiovasc. Genet. 8, 192\u2013206 (2015).","journal-title":"Circ. Cardiovasc. Genet."},{"issue":"9","key":"33507_CR53","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/aje\/kwx016","volume":"186","author":"Peter W\u00fcrtz","year":"2017","unstructured":"W\u00fcrtz, P. et al. Quantitative Serum NMR Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technology. Am. J. Epidemiol. https:\/\/doi.org\/10.1093\/aje\/kwx016 (2017).","journal-title":"American Journal of Epidemiology"},{"key":"33507_CR54","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/sj.hdy.6800717","volume":"95","author":"J Li","year":"2005","unstructured":"Li, J. & Ji, L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb). 95, 221\u2013227 (2005).","journal-title":"Heredity (Edinb)."},{"key":"33507_CR55","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jacc.2016.05.098","volume":"68","author":"F Baig","year":"2016","unstructured":"Baig, F., Pechlaner, R. & Mayr, M. Caveats of Untargeted Metabolomics for Biomarker Discovery. J. Am. Coll. Cardiol. 68, 1294\u20136 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"33507_CR56","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens, P. E. & Levin, A. & Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med. 158, 825\u201330 (2013).","journal-title":"Ann. Intern. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33507-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33507-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33507-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T05:03:53Z","timestamp":1720674233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-33507-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,15]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["33507"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-33507-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,15]]},"assertion":[{"value":"12 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PW is shareholder and employee of Nightingale Health Ltd, a company offering NMR-based metabolic profiling.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"15249"}}